Literature DB >> 31943018

Human iPSC-derived Down syndrome astrocytes display genome-wide perturbations in gene expression, an altered adhesion profile, and increased cellular dynamics.

Blandine Ponroy Bally1, W Todd Farmer1, Emma V Jones1, Selin Jessa1,2, J Benjamin Kacerovsky1, Alexandre Mayran3, Huashan Peng4,5,6, Julie L Lefebvre7, Jacques Drouin3, Arnold Hayer8, Carl Ernst4,5,6, Keith K Murai1,2.   

Abstract

Down syndrome (DS), caused by the triplication of human chromosome 21, leads to significant alterations in brain development and is a major genetic cause of intellectual disability. While much is known about changes to neurons in DS, the effects of trisomy 21 on non-neuronal cells such as astrocytes are poorly understood. Astrocytes are critical for brain development and function, and their alteration may contribute to DS pathophysiology. To better understand the impact of trisomy 21 on astrocytes, we performed RNA-sequencing on astrocytes from newly produced DS human induced pluripotent stem cells (hiPSCs). While chromosome 21 genes were upregulated in DS astrocytes, we found consistent up- and down-regulation of genes across the genome with a strong dysregulation of neurodevelopmental, cell adhesion and extracellular matrix molecules. ATAC (assay for transposase-accessible chromatin)-seq also revealed a global alteration in chromatin state in DS astrocytes, showing modified chromatin accessibility at promoters of cell adhesion and extracellular matrix genes. Along with these transcriptomic and epigenomic changes, DS astrocytes displayed perturbations in cell size and cell spreading as well as modifications to cell-cell and cell-substrate recognition/adhesion, and increases in cellular motility and dynamics. Thus, triplication of chromosome 21 is associated with genome-wide transcriptional, epigenomic and functional alterations in astrocytes that may contribute to altered brain development and function in DS.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2020        PMID: 31943018      PMCID: PMC7104679          DOI: 10.1093/hmg/ddaa003

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  110 in total

1.  Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain.

Authors:  Rong Mao; Carol L Zielke; H Ronald Zielke; Jonathan Pevsner
Journal:  Genomics       Date:  2003-05       Impact factor: 5.736

Review 2.  Astrocytes in neurodegenerative disease.

Authors:  Hemali Phatnani; Tom Maniatis
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-15       Impact factor: 10.005

Review 3.  Down syndrome and the complexity of genome dosage imbalance.

Authors:  Stylianos E Antonarakis
Journal:  Nat Rev Genet       Date:  2016-12-28       Impact factor: 53.242

4.  Efficient generation of astrocytes from human pluripotent stem cells in defined conditions.

Authors:  Atossa Shaltouki; Jun Peng; Qiuyue Liu; Mahendra S Rao; Xianmin Zeng
Journal:  Stem Cells       Date:  2013-05       Impact factor: 6.277

5.  Homocysteine metabolism in children with Down syndrome: in vitro modulation.

Authors:  M Pogribna; S Melnyk; I Pogribny; A Chango; P Yi; S J James
Journal:  Am J Hum Genet       Date:  2001-06-05       Impact factor: 11.025

Review 6.  Stem and progenitor cell dysfunction in human trisomies.

Authors:  Binbin Liu; Sarah Filippi; Anindita Roy; Irene Roberts
Journal:  EMBO Rep       Date:  2014-12-17       Impact factor: 8.807

Review 7.  Astrocytes: biology and pathology.

Authors:  Michael V Sofroniew; Harry V Vinters
Journal:  Acta Neuropathol       Date:  2009-12-10       Impact factor: 17.088

8.  Domains of genome-wide gene expression dysregulation in Down's syndrome.

Authors:  Audrey Letourneau; Federico A Santoni; Ximena Bonilla; M Reza Sailani; David Gonzalez; Jop Kind; Claire Chevalier; Robert Thurman; Richard S Sandstrom; Youssef Hibaoui; Marco Garieri; Konstantin Popadin; Emilie Falconnet; Maryline Gagnebin; Corinne Gehrig; Anne Vannier; Michel Guipponi; Laurent Farinelli; Daniel Robyr; Eugenia Migliavacca; Christelle Borel; Samuel Deutsch; Anis Feki; John A Stamatoyannopoulos; Yann Herault; Bas van Steensel; Roderic Guigo; Stylianos E Antonarakis
Journal:  Nature       Date:  2014-04-17       Impact factor: 49.962

9.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

10.  Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling.

Authors:  Stuart M Chambers; Christopher A Fasano; Eirini P Papapetrou; Mark Tomishima; Michel Sadelain; Lorenz Studer
Journal:  Nat Biotechnol       Date:  2009-03-01       Impact factor: 54.908

View more
  13 in total

1.  Down-syndrome-induced senescence disrupts the nuclear architecture of neural progenitors.

Authors:  Hiruy S Meharena; Asaf Marco; Vishnu Dileep; Elana R Lockshin; Grace Y Akatsu; James Mullahoo; L Ashley Watson; Tak Ko; Lindsey N Guerin; Fatema Abdurrob; Shruthi Rengarajan; Malvina Papanastasiou; Jacob D Jaffe; Li-Huei Tsai
Journal:  Cell Stem Cell       Date:  2022-01-06       Impact factor: 24.633

2.  APP and DYRK1A regulate axonal and synaptic vesicle protein networks and mediate Alzheimer's pathology in trisomy 21 neurons.

Authors:  Chun-I Wu; Elizabeth A Vinton; Richard V Pearse; Keunjung Heo; Aimee J Aylward; Yi-Chen Hsieh; Yan Bi; Sopefoluwa Adeleye; Seeley Fancher; Duc M Duong; Nicholas T Seyfried; Thomas L Schwarz; Tracy L Young-Pearse
Journal:  Mol Psychiatry       Date:  2022-02-23       Impact factor: 13.437

Review 3.  Cell models for Down syndrome-Alzheimer's disease research.

Authors:  Yixing Wu; Nicole R West; Anita Bhattacharyya; Frances K Wiseman
Journal:  Neuronal Signal       Date:  2022-04-08

4.  Building the Future Therapies for Down Syndrome: The Third International Conference of the T21 Research Society.

Authors:  Mara Dierssen; Yann Herault; Pablo Helguera; Maria Martínez de Lagran; Anna Vazquez; Bradley Christian; Maria Carmona-Iragui; Frances Wiseman; William Mobley; Elizabeth M C Fisher; Veronique Brault; Anna Esbensen; Lisa M Jacola; Marie Claude Potier; Eric D Hamlett; Leonard Abbeduto; Laura Del Hoyo Soriano; Jorge Busciglio; Maria Florencia Iulita; John Crispino; Sébastien Malinge; Eugenio Barone; Marzia Perluigi; Floriana Costanzo; Jean Maurice Delabar; Renata Bartesaghi; Alain D Dekker; Peter De Deyn; Juan Fortea Ormaechea; Patricia A Shaw; Tarik F Haydar; Stephanie L Sherman; André Strydom; Anita Bhattacharyya
Journal:  Mol Syndromol       Date:  2021-05-20

Review 5.  Meta-analysis of metabolites involved in bioenergetic pathways reveals a pseudohypoxic state in Down syndrome.

Authors:  Laszlo Pecze; Elisa B Randi; Csaba Szabo
Journal:  Mol Med       Date:  2020-11-09       Impact factor: 6.354

Review 6.  Astrocytic Factors Controlling Synaptogenesis: A Team Play.

Authors:  Giuliana Fossati; Michela Matteoli; Elisabetta Menna
Journal:  Cells       Date:  2020-09-26       Impact factor: 6.600

Review 7.  Clustered Protocadherins Emerge as Novel Susceptibility Loci for Mental Disorders.

Authors:  Zhilian Jia; Qiang Wu
Journal:  Front Neurosci       Date:  2020-11-12       Impact factor: 4.677

Review 8.  Modeling Neurodevelopmental and Neuropsychiatric Diseases with Astrocytes Derived from Human-Induced Pluripotent Stem Cells.

Authors:  Baiyan Ren; Anna Dunaevsky
Journal:  Int J Mol Sci       Date:  2021-02-08       Impact factor: 5.923

Review 9.  Rethinking Intellectual Disability from Neuro- to Astro-Pathology.

Authors:  Álvaro Fernández-Blanco; Mara Dierssen
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

10.  A human isogenic iPSC-derived cell line panel identifies major regulators of aberrant astrocyte proliferation in Down syndrome.

Authors:  Keiji Kawatani; Toshihiko Nambara; Nobutoshi Nawa; Hidetaka Yoshimatsu; Haruna Kusakabe; Katsuya Hirata; Akira Tanave; Kenta Sumiyama; Kimihiko Banno; Hidetoshi Taniguchi; Hitomi Arahori; Keiichi Ozono; Yasuji Kitabatake
Journal:  Commun Biol       Date:  2021-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.